Rigel Pharmaceuticals
As of the edition of 20 October 2026, Rigel Pharmaceuticals runs 6 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fostamatinib | Ends 2031 (patent) | 3 |
| Vepdegestrant | Ends 2038 (patent) | 1 |
| Olutasidenib | Ends 2039 (patent) | 1 |
| Pralsetinib | Ends 2042 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Rigel Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 14 trials led
- Blood and lymph: 9 trials led
- Skin and connective tissue: 4 trials led